MFMing Fang

Ming Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ming Fang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GSTP1/JNK-Linked Redox Dysregulation in Amyotrophic Lateral Sclerosis: Evidence, Controversies, and a Testable Framework

    by Jinli Feng, Jinming Han, Ming Fang, Xinyuan Pang, Feng Qiu, Hongfen Wang

    Amyotrophic lateral sclerosis (ALS) is biologically heterogeneous, and oxidative injury can contribute to degeneration while also reflecting downstream damage or adaptive responses. Glutathione S-transferase Pi 1 (GSTP1) combines glutathione-dependent detoxification with non-canonical regulation of c-Jun N-terminal kinase (JNK), but the biochemical evidence for direct GSTP1–JNK coupling largely comes from non-ALS systems. This narrative review separates human ALS observations, functional ALS-model findings, and extrapolated mechanisms. Altered GSTP1 abundance or total GST activity in ALS does not establish GSTP1-specific impairment or causality. JNK-related injury has stronger functional support in selected ALS models involving DLK/MAP3K12, ASK1, HIPK2, and MAP4K4. Ferroptosis-related findings are concentrated in SOD1 models, with additional evidence of susceptibility in FUS cellular models, and do not establish a GSTP1–JNK–ferroptosis cascade. We distinguish neuronal and glial context and the execution of apoptosis versus ferroptosis. Decisive tests combine GSTP1 perturbation with catalytic and interaction-deficient rescue, direct binding and JNK-activity assays, and pathway-specific cell-death rescue. GSTP1 remains a candidate context-dependent modifier of shared neurodegenerative processes; causal validation, reproducible pathway biomarkers, and safety assessment are required before therapeutic translation.